Volume 34, Issue 241 (1-2025)
J Mazandaran Univ Med Sci 2025, 34(241): 133-148 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mojarad-Jabali S, Molavipordanjani S. Lead-212 Radiopharmaceuticals for Receptor-Targeted Radionuclide Therapy. J Mazandaran Univ Med Sci 2025; 34 (241) :133-148
URL: http://jmums.mazums.ac.ir/article-1-21231-en.html
URL: http://jmums.mazums.ac.ir/article-1-21231-en.html
Abstract: (538 Views)
Receptor-targeted radionuclide therapy (RTRT) combines the power of particle-emitting radionuclides with the receptor-targeting capabilities of biomolecules, including antibodies and peptides. There are numerous radionuclides, but only a handful possess the necessary characteristics for targeted alpha therapy (TAT). Among them are actinium-225 (²²⁵Ac), bismuth-213 (²¹³Bi), radium-224 (²²⁴Ra), lead-212 (²¹²Pb), thorium-227 (²²⁷Th), astatine-211 (²¹¹At), and terbium-149 (¹⁴⁹Tb). Lead-212 (²¹²Pb) is a radionuclide that release both alpha and beta particles during its decay. The distinctive properties of ²¹²Pb, such as its relatively short half-life (10.64 hours), the commercial availability of ²²⁴Ra/²¹²Pb generators, in vivo generation of alpha particles through ²¹²Bi at its target site, simple conjugating process, and strong binding to chelators such as DOTA and TCMC make this radionuclide particularly promising for targeted alpha therapy. TAT with ²¹²Pb has demonstrated significant therapeutic effectiveness in both in vitro and in vivo models. To date, numerous biological molecules, including antibodies and peptides, have been labeled with ²¹²Pb in preclinical studies to evaluate their therapeutic efficacy and receptor-targeting potential. These studies have focused on receptors such as the epidermal growth factor receptor (EGFR) family, somatostatin receptor 2 (SSTR2), melanocortin 1 receptor (MC1R), prostate-specific membrane antigen (PSMA), CD37, CD38, CD46, vascular cell adhesion molecule 1 (VCAM-1), and chondroitin sulfate proteoglycan 4 (CSPG4). This review will first examine the physical properties of ²¹²Pb, followed by an analysis of its chemical characteristics, particularly its interactions with DOTA and TCMC. Finally, it will explore preclinical studies on ²¹²Pb-radiolabeled molecules and assess the clinical applications of radiotracers developed for receptor-targeted radionuclide therapy.
Type of Study: Review |
Subject:
general practitioner
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
